{
    "organizations": [],
    "uuid": "abef65767f96d584a0da670fc78e511a1c826cb1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-merck-kgaa-announces-positive-phas/brief-merck-kgaa-announces-positive-phase-iib-results-for-evobrutinib-in-relapsing-multiple-sclerosis-idUSFWN1QP0RY",
    "ord_in_thread": 0,
    "title": "BRIEF-Merck KGaA Announces Positive Phase IIb Results For Evobrutinib In Relapsing Multiple Sclerosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7 (Reuters) - Merck KGaA:\n* MERCK KGAA, DARMSTADT, GERMANY, ANNOUNCES POSITIVE PHASE IIB RESULTS FOR EVOBRUTINIB IN RELAPSING MULTIPLE SCLEROSIS\n* MERCK KGAA - STUDY HAS MET ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-07T23:20:00.000+02:00",
    "crawled": "2018-03-07T18:02:25.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "merck",
        "kgaa",
        "merck",
        "kgaa",
        "darmstadt",
        "germany",
        "announces",
        "positive",
        "phase",
        "iib",
        "result",
        "evobrutinib",
        "relapsing",
        "multiple",
        "sclerosis",
        "merck",
        "kgaa",
        "study",
        "met",
        "primary",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}